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Abstract
Introduction and objective. The introduction of a vaccine against hepatitis B virus (HBV) for newborn babies in Italy in 
1991, extended to 12-year-old children for the first 12 years of application, has been a major achievement in terms of the 
prevention of HBV infection. The objective of this study was to analyse the long-term immunogenicity and effectiveness 
of HBV vaccination among healthcare students with different working seniorities.  
Materials and method. A cross-sectional observational study of undergraduate and postgraduate students attending 
the Medical School of the University of Palermo was conducted from January 2014 – July 2016. HBV serum markers were 
performed with commercial chemiluminescence assays. Categorical variables were analyzed using the chi-square test 
(Mantel–Haenszel), whereas means were compared by using the Student’s t test. Adjusted odds ratios (ORs) and 95% 
confidence intervals (CIs) were also calculated by a multivariable logistic regression, using a model constructed to examine 
predictors of anti-HBs titer above 10 mIU/mL, assumed as protective.  
Results. Of the 2,114 subjects evaluated – all vaccinated at infancy or at the age of 12 years and were HBsAg/anti-HBc 
negative – 806 (38.1%) had an anti-HBs titre <10 IU/L. The latter were younger, more likely to be attending a healthcare 
profession school (i.e., nursing and midwifery), than a medical postgraduate level school, and more likely to have been 
vaccinated in infancy (p <0.001, 95% CI 2.63–5.26, adjusted OR 3.70).  
Conclusion. The results of the study suggest that assessment of HBV serum markers in workers potentially exposed to 
hospital infections is useful for identifying small numbers of unvaccinated subjects, or vaccinated subjects with low antibody 
titre, all of whom should be referred to a booster series of vaccinations.
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INTRODUCTION
Hepatitis B infection has a variety of clinical course, including 
self-limited acute hepatitis, fulminant hepatic failure, chronic 
hepatitis, and progression to cirrhosis and hepatocellular 
carcinoma. HBV is transmitted by percutaneous or mucosal 
exposure to infected blood or other body fluids. In July 2016, 
the World Health Organization (WHO) estimated that 240 
million people are chronically infected with HBV, and more 
than 686,000 people die every year due to complications 
of hepatitis B, including cirrhosis and liver cancer [1]. The 
WHO’s data reported that the hepatitis B prevalence is 
highest in sub-Saharan Africa and East Asia, where between 
5–10% of the adult population is chronically infected. High 
rates of chronic infections are also found in the Amazon and 
the southern parts of Eastern and Central Europe. In the 
Middle East and the Indian subcontinent, an estimated 2–5% 
of the general population are chronically infected. Less than 
1% of the population of Western Europe and North America 
is chronically infected [1].
Worldwide, two billion people are infected with HBV (1/3 
of the world’s population), and there are four million new 
cases of acute hepatitis per year, with almost 400 million 
chronic carriers [2].
In countries where large-scale vaccination efforts were 
made, the epidemiology of hepatitis B has been transformed. 
In Italy, the epidemiology of this infection changed after the 
introduction in 1991 of the vaccination of newborn babies 
that was extended to 12-year-old children for the first 12 years 
of application.
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In Italy, from 1985–2014 in Italy, there has been a reduction 
in new notified cases: from 12 per 100,000 inhabitants to <1, 
as reported by the Integrated Epidemiological System for 
Acute Viral Hepatitis (SEIEVA) [2]. The Italian recommended 
adult/adolescent immunization schedule involves HBV 
vaccination doses at months 0, 1, and 6, whereas infant 
vaccination starts from the third month of life for infants, 
with 2nd and 3rd doses at 5 and 11 months. The vaccine is 95% 
effective in preventing infection and the development of 
chronic disease and liver cancer due to hepatitis B. In Italy, 
HBV vaccination is also recommended for people at risk of 
acquiring HBV infection, including those with important 
occupational risk as health workers [3–5]. In Italy, according 
to the national laws, students are also considered as workers, 
and therefore, if they are exposed to physical, chemical, 
biological or psychological risks, they are evaluated by an 
occupational health physician.
Of the population undergoing to HBV vaccination, 95% 
develop an effective immune response evaluated by the level of 
antibodies antiHBsAg > 10 mIU/mL. Several studies confirm 
that the acquired immunity persists for at least 10 years after 
vaccination with level of antibodies > 10 mIU/mL, but probably 
not longer, if vaccination had been performed at neonatal age 
[6–7]. In several countries in the world, students of faculties 
of medicine are examined to establish if the vaccination 
performed in infancy is still protective several decades after 
HBV vaccinations, because this is a population occupationally-
exposed to a higher risk of acquiring HBV infection [8–20].
OBJECTIVE
The main aim of this study was to evaluate the persistence 
of long-term immunogenicity of HBV in students of the 
School of Medicine at the University of Palermo. A second 
aim was to identify possible predictive factors of long-term 
immunogenicity, such as age of individuals when they were 
vaccinated, gender and race.
MATERIALS AND METHOD
In this cross-sectional observational study, the levels of 
serum HBsAg, anti-HBs, and anti-HBc were evaluated of 
students attending schools of the health care professions, or 
postgraduate medical schools of the University of Palermo, 
Italy, who were examined for professional risks from January 
2014 – July 2016. For each student, a standardized medical 
record was compiled, including socio-demographic (age, 
gender, country of origin) and clinical information (relatives’ 
diseases and personal remote and proximate pathologies). A 
personal objective exam was additionally conducted for each 
subject before blood sampling.
Arbitrarily excluded from the study were subjects 
who met at least one of the following exclusion criteria: 
a) HBsAg personal or maternal positivity, chronic diseases 
or immunosuppression; b) absence of primary documentation 
of vaccination for HBV; c) recent booster dose of HBV vaccine.
According to Italian law, the subjects were requested to 
provide written informed consent to the processing of data. 
Moreover, although it is not required in Italy for observational 
studies, approval of the Local Ethics Committee was aldso 
obtained [21].
Serological tests. Serological analyses were performed with 
commercial chemiluminescence assays (VITROS anti-HBs 
assay on the Vitros ECI Immunodiagnostic system, Ortho-
Clinical Diagnostics, UK). In particular, the antibody 
to the hepatitis B surface antigen (anti-HBs) levels were 
expressed as mIU/mL. Dynamic range of quantification is 
10–1000 mIU/ml. The level of anti-HBs above 10 mIU/mL 
was considered as protective against HBV infection.
Statistical analysis. Statistical analysis was performed with 
R software version 3.3.2 (October 2016). The significance level 
chosen for all analyses was.05, 2-tailed. Absolute and relative 
frequencies were calculated for qualitative variables, whereas 
normally distributed quantitative variables were summarized 
as mean (standard deviation). Data normality was verified 
by the Shapiro–Wilk test for normality. Categorical variables 
were analyzed using the chi-square test (Mantel–Haenszel), 
means were compared by using the Student’s t test. Adjusted 
odds ratios (ORs) and 95% confidence intervals (CIs) were 
also calculated by a multivariable logistic regression model 
constructed to examine predictors of anti-HBs titer above 
10 mIU/mL assumed as protective. All variables found to 
have a statistically significant association (P <.05) with anti-
HBs titer > 10 mIU/mL were entered in multivariate logistic 
regression model in order to check for independence. In 
the multivariate analysis, age was included as a continuous 
variable.
RESULTS
The main characteristics of the 2,114 subjects included in the 
study are shown in Table 1.
All enrolled subjects were vaccinated for HBV and HBsAg/
anti-HBc negative. 2, 870 (41.1%) students received a course of 
3 paediatric doses (10 μg) of recombinant hepatitis B vaccine 
at their 3rd, 5th and 11th month of postnatal life, and 1,244 
(58.9%) received a course of 3 adult doses (20 μg) of the same 
vaccine when they were 12 years old, as required by current 
law in Italy [22] The majority (61.9 %) of the students had an 
anti-HBs titre >10 mIU/mL (Tab. 2).
Students with protective anti-HBs titre were statistically 
significantly older (27.9 vs. 24.4 years, p<0.001), with fewer 
years after HBV vaccination (19.2 vs. 20.1, p<0.001), 
Table 1. General characteristics of subjects (N=2,114) included in the study
Total of students
Total, n (%) 2,114 (100)
Sex, n (%)
– Males 1,275 (60.3)
– Females 839 (39.7)
Age in years, mean ± SD 26.6 ± 5.4
Country of birth, n (%)
– Italy 2,112 (99.9)
– Poland 1 (0.05)
– Madagascar 1 (0.05)
University course, n (%)
– Healthcare profession School 1,096 (51.8)
– Postgraduate medical School 1,018 (48.2)
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vaccinated at age 12 years (76.0% with ≥ vs. 41.7% among 
vaccinate at infancy, p<0.001) and more frequently attending 
postgraduate medical school (77.4% with ≥ vs. 47.4% among 
healthcare profession school, p<0.001). No statistically 
significant differences were observed in antibody titer 
between males and females.
The multivariable logistic regression model (Tab. 3) shows 
that after controlling for confounding, HBV vaccination at 
age of 12 years and attending postgraduate medical school, 
were significantly associated with increased odds of having 
protective Hepatitis B surface antibody titers (OR=3.70, 95% 
CI =2.63–5.26 and OR=1.40, 95% CI =1.02–1.94, respectively). 
In particular, a protective anti-HBV titer was about 4-fold 
more frequent among subjects vaccinated during adolescence 
than those vaccinated at infancy.
DISCUSSION AND CONCLUSIONS
Health-care-related transmission has long been recognized 
as an important source of new HBV infections worldwide. 
It is estimated that in the United States, 12,000 health care 
workers were infected per year in the prevaccine era. A health 
care worker’s risk of infection has been shown to correlate 
with level of blood and needle exposure [22].
It is internationally recognized that the healthcare 
profession and postgraduate medical students have a high 
occupational risk for HBV infection, also in countries with a 
low incidence of the disease [10–11,14]. In Italy, several studies 
have demonstrated a low endemic level (prevalence of HBsAg 
in the general population <2%) with an incidence of HBV 
infections of about 1 per 100,000 individuals, suggesting 
that healthcare workers and students could have a risk that 
is low but not negligible. Despite such evidence, for health 
professionals as well as for students and volunteers, to-date 
there is no obligation of vaccination, which is recommended 
only [23,24]. Fortunately a large majority of young Italian 
students have been vaccinated according to the national 
immunization programme that, since 1991, has included 
HBV vaccination as compulsory for infants and adolescents 
aged 12 years. Adolescent’s vaccination was restricted to the 
first 12 years of the implementation of the vaccination law 
and, thus, in 2004, vaccination of 12-year-olds was stopped, 
but retained for infants.
As demonstrated by several studies, administration of HBV 
as part of a combination vaccine or as a monovalent vaccine 
induces long-lasting immune memory against HBV with long 
term antibody persistence. Several studies have reported that 
85–90% of those vaccinated as adolescents have anti-HBs 
levels >10 mIU/mL when measured 10 years after vaccination. 
This percentage was 40–60 % for those vaccinated as infants, 
as measured 15–20 years after vaccination [25–26]. Both these 
data coincide with results obtained by the authors of the 
presented study, since more than 60% of their students had 
anti-HBV titers above 10 mUI/mL, also more than 20 years 
after vaccination. Moreover, it should be pointed out that none 
of them received a booster dose after the primary vaccination 
programme, and in the primary documentation of vaccination 
for HBV no date was indicated for its administration. In the 
experience of the authors, they observed that this habit is 
also common among the general population.
Despite declining serum levels of antibody, international 
evidence shows that vaccine-induced immunity continues to 
prevent clinical disease or detectable viremic HBV infection. 
The long-term efficacy of HBV vaccination is confirmed when 
one considers that none of vaccinated subjects in the current 
study was found to be HBsAg/anti-HBc positive.
As already reported by several authors, including those of 
the presented study, a relatively high percentage of students 
(about 40%) were revealed as having anti-HBV titers below 
10 mIU/mL.
The CDC recommend pre-exposure assessment of current 
or past anti-HBs results upon matriculation, followed by one 
or more additional doses of HBV vaccine for subjects with 
anti-HBs <10 mIU/mL, if necessary, helps to ensure HBV 
protection after contacts with blood or body fluids [27].
The administration of an HBV challenge dose after the 
primary schedule, induces strong anamnestic responses and 
is well tolerated [28]. In Italy, for Medical School students it 
is necessary to assess anti-HBs titre before making stages in 
hospital, in order to identify subjects with levels <10 mIU/
mL. In fact, although the current WHO view is that subjects 
with an anti-HBs titre <10 mIU/mL still retain memory 
immunity, and no booster dose is necessary as part of a 
routine immunization programme, it could be beneficial 
to have a more protective approach for healthcare workers 
who are at significantly higher risk of exposure to HBV, 
administering a booster dose and rechecking titre after 1–2 
Table 2. Variables associated with persistence of protective Hepatitis B 
surface antibody titers (≥ 10 mIU/mL)
Hepatitis B surface antibody 
titers
p-value
≥ 10 mIU/mL < 10 mIU/mL
Total, n (%) 1,308 (61.9) 806 (38.1) –
Sex, n (%)
– Males 513 (61.1) 326 (37.6)
0.58
– Females 795 (62.4) 480 (38.9)
Age in years, mean ± SD 27.9±5.01 24.4±5.47 <0.001
Years since HBV vaccination, mean ± SD 19.2±3.57 20.1±3.24 <0.001
Vaccination period, n (%)
– Vaccinated at infancy 363 (41.7) 507 (58.3)
<0.001
– Vaccinated at age 12 years 945 (76.0) 299 (24.0)
University course, n (%)
– Healthcare profession school 520 (47.4) 576 (52.6)
<0.001
– Postgraduate medical school 788 (77.4) 230 (22.6)
Table 3. Multivariable logistic regression model including variables 
statistically significantly associated with Hepatitis B surface antibody 
titers ≥ 10 mIU/mL
Adjusted OR (95% CI)
Age in years 0.81 (0.40 – 1.65)
Years since HBV vaccination 1.02 (0.99 – 1.05)
Vaccination period
– Vaccinated at infancy referent
– Vaccinated at age 12 years 3.70 (2.63 – 5.26)
University course
– Healthcare profession school referent
– Postgraduate medical school 1.40 (1.02 – 1.94)
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months to verify whether or not they are responders [29]. The 
screening in the healthcare cathegories is also fundamental 
to identify students and workers older than 35 years old, 
that have not been vaccinated, neither at birth or at 12 years 
of age, and immigrants from countries without universal 
immunization. This approach would allow identification of 
non-responders to the primary vaccination cycle or subjects 
with incomplete vaccination cycle.
Moreover we have found that two variables could help in 
predicting subjects at higher risk of having anti-HBs titre <10 
mIU/mL. These variables are HBV vaccination at infancy 
and attending healthcare professional courses.
The possible causes of the low anti-HBs titres in adult 
subjects vaccinated in infancy could be due to the immaturity 
of the immune system in infants, at an age of life when there 
could be a lower interaction between B and T lymphocytes. 
Otherwise, it is less clear the reason for which students 
attending healthcare professional courses could have a higher 
risk of non-protective HBV titers’, also after adjustment for 
confounding due to age, years after vaccination and vaccination 
period. Further analyses could be needed for answering to this 
intriguing question and some variables, as socio-demographic 
characterists could play a role in this association.
In this sense, the lack of more information about students 
(e.g. anti- HBV vaccine used for primary cycle, socio-
demographic characteristics, immunological status, previous 
blood exposure etc) represents a major limit of the presented 
study. Despite these limitations, the presented study enriches 
the litterature on HBV vaccination, highlighting that although 
anti-HBV vaccination is associated with long persistence of 
protective titers, several students and post-graduates of the 
Medical School could benefit from a booster dose.
Moreover, some factors were found that could contribute 
to identify susceptible subjects and that could be associated 
with immune regulation pattern. Long-term follow-up studies 
several decades after vaccination administration will be needed 
to confirm the duration and persistence of immune memory.
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